## Answer
(model generated chain of thought explanation)

To answer this question, let's break down the key concepts related to bortezomib and its mechanism of action.

1. **Understanding Bortezomib**: Bortezomib is a proteasome inhibitor used in the treatment of certain cancers, including mantle cell lymphoma. It works by blocking the 26S proteasome, a protein complex that degrades ubiquitinated proteins.

2. **Mechanism of Action**: The primary mechanism through which bortezomib exerts its effects is by inhibiting the ubiquitin-proteasome pathway (UPP). This pathway is crucial for protein degradation and cell cycle regulation. By blocking the proteasome, bortezomib prevents the breakdown of certain proteins that are involved in cell signaling pathways.

3. **Effect on Protein Degradation**: The key effect of bortezomib is to accumulate ubiquitinated proteins within cells. This accumulation leads to a disruption in normal cellular processes, including cell cycle regulation and apoptosis (programmed cell death).

4. **Comparison with Other Options**:
   - A. Stabilization of tubulin polymers: This is more related to the mechanism of action of drugs like paclitaxel, which stabilizes microtubules and prevents their disassembly.
   - C. Preventing the relaxation of DNA supercoils: This describes the mechanism of action of topoisomerase inhibitors, such as etoposide, which prevent DNA replication by inhibiting topoisomerase enzymes.
   - D. Inhibition of tyrosine kinase receptors: This is more related to the mechanism of action of targeted therapies like imatinib, which specifically inhibit certain tyrosine kinases involved in cancer cell signaling.

Given this understanding, let's evaluate the answer choices:

- B. Accumulation of ubiquitinated proteins: This accurately describes the primary effect of bortezomib.
- A. Stabilization of tubulin polymers: Incorrect, as this is more related to paclitaxel.
- C. Preventing the relaxation of DNA supercoils: Incorrect, as this is more related to topoisomerase inhibitors.
- D. Inhibition of tyrosine kinase receptors: Incorrect, as bortezomib targets a different pathway.

Therefore, the best answer is B.